Story perspectives

FDA Approves Boehringer's HERNEXEOS for Lung Cancer Treatment

10/22/2025

37 7

Summary

Story summary

Boehringer Ingelheim's HERNEXEOS (zongertinib tablets) received FDA approval to treat adult patients with HER2-mutant non-small cell lung cancer.
The Oncomine Dx Target Test was approved as a companion diagnostic to identify eligible patients.
In clinical trials, 75% of participants experienced tumor shrinkage.
Imaging advances such as 18F-FAPI PET/CT show promise for detecting brain metastases in lung cancer.
Multi-cancer early detection tests are emerging to improve screening and could transform U.S. healthcare.

1 of 1

Story summary

Boehringer Ingelheim's HERNEXEOS (zongertinib tablets) received FDA approval to treat adult patients with HER2-mutant non-small cell lung cancer.
The Oncomine Dx Target Test was approved as a companion diagnostic to identify eligible patients.
In clinical trials, 75% of participants experienced tumor shrinkage.
Imaging advances such as 18F-FAPI PET/CT show promise for detecting brain metastases in lung cancer.
Multi-cancer early detection tests are emerging to improve screening and could transform U.S. healthcare.